Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant.

[1]  R. E. Hoekstra,et al.  Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. , 1991, Pediatrics.

[2]  D. Heilbron,et al.  Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. , 1991, Pediatrics.

[3]  J. Gilhooly,et al.  Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. , 1991, Pediatrics.

[4]  J. Neilson,et al.  Oxford Database of Perinatal Trials , 1991 .

[5]  Newborn.  Surfactant Replacement Therapy for Respiratory Distress Syndrome , 1991, Pediatrics.

[6]  F. Volberg,et al.  Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I. , 1991, The Journal of pediatrics.

[7]  G. Heldt,et al.  Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. , 1991, The Journal of pediatrics.

[8]  D. Phelps,et al.  A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. , 1991, The New England journal of medicine.

[9]  M. Avery,et al.  Surfactant-replacement therapy. , 1991, The New England journal of medicine.

[10]  F. Possmayer,et al.  Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. , 1991, Pediatrics.

[11]  F. Walther,et al.  Cerebral blood flow velocity after surfactant instillation in preterm infants. , 1991, The Journal of pediatrics.

[12]  S. Goldman,et al.  Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1. , 1991, The Journal of pediatrics.

[13]  C. Bose,et al.  Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. , 1990, The Journal of pediatrics.

[14]  M. Fujimura,et al.  Surfactant Replacement Therapy With a Single Postventilatory Dose of a Reconstituted Bovine Surfactant in Preterm Neonates With Respiratory Distress Syndrome: Final Analysis of a Multicenter, Double-blind, Randomized Trial and Comparison With Similar Trials , 1990, Pediatrics.

[15]  C. Morley,et al.  Follow up of premature babies treated with artificial surfactant (ALEC). , 1990, Archives of disease in childhood.

[16]  R. E. Hoekstra,et al.  Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group. , 1990, Pediatrics.

[17]  M. McCormick,et al.  Health and developmental outcomes of a surfactant controlled trial: follow-up at 2 years. , 1990, Pediatrics.

[18]  D. Phelps,et al.  Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. , 1988, Pediatrics.

[19]  G. Enhorning,et al.  Two-year follow-up of infants enrolled in a randomized trial of surfactant replacement therapy for prevention of neonatal respiratory distress syndrome. , 1988, Pediatrics.

[20]  A. Ohlsson,et al.  Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. , 1988, Pediatrics.

[21]  Y. Vaucher,et al.  Neurodevelopmental and respiratory outcome in early childhood after human surfactant treatment. , 1988, American journal of diseases of children.

[22]  O. Brouwer.  Neurologic assessment during the first year of life By Claudine Amiel-Tison and Albert Grenier, Oxford University Press, New York-Oxford, 1986. xiv + 197 pages , 1987, Journal of the Neurological Sciences.

[23]  F. Gilles,et al.  Focal necrosis of the white matter (periventricular leukomalacia): sonographic, pathologic, and electroencephalographic features. , 1986, AJNR. American journal of neuroradiology.

[24]  C. Amiel‐Tison,et al.  Neurological Assessment During the First Year of Life , 1986 .

[25]  K. Benirschke,et al.  Prophylactic treatment of very premature infants with human surfactant. , 1986, The New England journal of medicine.

[26]  H. Halliday,et al.  Growth and development two years after artificial surfactant replacement at birth. , 1986, Early human development.

[27]  L. Papile,et al.  Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. , 1978, The Journal of pediatrics.

[28]  A. Rimm,et al.  Surfactant replacement therapy in respiratory distress syndrome. Meta-analysis of clinical trials of single-dose surfactant extracts. , 1991, American journal of diseases of children.

[29]  Isaac Ben-Sira,et al.  An international classification of retinopathy of prematurity. Clinical experience. , 1985, Ophthalmology.

[30]  P. Farrell,et al.  Lung development : biological and clinical perspectives , 1982 .

[31]  D. K. Edwards.  4 – Radiology of Hyaline Membrane Disease, Transient Tachypnea of the Newborn, and Bronchopulmonary Dysplasia , 1982 .